Walvax Biotechnology News

Watson Biotech (300142) 2023 Three Quarter Report Commentary: PCV13 Indonesia Approved for Listing Q3 Results Under Short-Term Pressure

Oct 31, 2023 16:26

Watson Biology (300142) 2023 Interim Report Review: HPV Vaccine Competition Exceeds Expectations and Internationalization Accelerates

中信證券Sep 7, 2023 00:00

Watson Biotech (300142): 13-valent pneumonia and bivalent HPV dual-wheel drive performance continues to grow rapidly

中信證券Apr 4, 2023 00:00

Watson Biotech (300142): Rapid growth in research and development of two major vaccines is progressing steadily

東莞證券Oct 25, 2022 15:21

Watson Biotech (300142) Review Report: Innovative Products Benefit, Overseas Markets Reach Higher Level

國海證券Aug 15, 2022 00:00

Watson Biotech (300142): First-time exporter of 13-valent pneumonia saw a high increase in revenue

海通證券Aug 14, 2022 00:00

Watson Biotech (300142): The 13-valent pneumonia and HPV vaccine dosage innovative product echelon is growing

光大證券Aug 11, 2022 16:06

Watson Biotech (300142): The release of major products accelerates the construction of a new platform for COVID-19 vaccine technology

申萬宏源研究Aug 11, 2022 14:36

Deepin*Company*Watson Biotech (300142): PCV13 continues to grow, and the HPV2+ mRNA vaccine is worth looking forward to

中銀證券Apr 29, 2022 17:36

Watson Biotech (300142): 13-valent pneumonia is growing steadily, COVID-19 vaccine layout is complete

海通證券Mar 23, 2022 13:57

Watson Biotech (300142): Cash flow situation has improved dramatically, R&D projects and industrialization are progressing steadily

光大證券Mar 22, 2022 15:22

Watson Biotech (300142): OMICRON's continuous fermentation curve overtaking opportunities are highlighted

東北證券Dec 17, 2021 00:00

Watson Biology (300142) 2021 mid-report comments: 13 price sales volume in line with expectations waiting for phase III clinical results of MRNA COVID-19 vaccine

中信證券Sep 7, 2021 00:00

Deepin* Company* Watson Biotech (300142): Deepening the field of mRNA vaccines in all directions can be expected in the future

中銀證券Aug 30, 2021 00:00

Watson Biotech (300142): PCV13 continues to release volume and comprehensively lays out the MRNA technology platform

招商證券Aug 30, 2021 00:00

Watson Biology (300142): Q2 single-quarter sales steadily resume 13-price pneumonia volume is expected

中信建投證券Aug 17, 2021 00:00

Deepin* Company* Watson Biotech (300142): Deeply involved in the vaccine industry and is committed to building the first domestically produced MRNA vaccine in China

中銀證券Jul 5, 2021 00:00

Watson Biology (300142) Quarterly report 2021 Preview comments: strong growth in issuance of 13-valent pneumonia conjugate vaccine batches without affecting current performance through profit or loss

光大證券Apr 11, 2021 00:00

Watson Biotech (300142) 2020 Report Review: Performance Meets Expectations Rapid Release of the 13-Valent Pneumonia Vaccine

光大證券Mar 28, 2021 00:00

Deepin*Company*Watson Biotech (300142): PCV13's Successful Release Incentive Plan Shows Confidence

中銀證券Nov 30, 2020 00:00